Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Ablynx Announces 2012 Full Year Results Year of Strong Operational and Financial Progress


Print article Print article
© Marketwire 2013
2013-02-27 08:31:26 - Regulated Information

GHENT, BELGIUM -- (Marketwire) -- 02/27/13 -- Ablynx (EURONEXT BRUSSELS: ABLX) today announced its consolidated results for 2012, which have been prepared in accordance with IFRS as adopted by the European Union.



Operating highlights



  • First Nanobody®, ALX-0171 (anti-RSV), successfully delivered directly into the lungs using a nebuliser

  • Second clinical proof-of-concept for Nanobodies achieved with the anti-IL-6R product, ALX-0061, in RA patients

  • Three pre-clinical candidates selected as part of the Strategic Alliance with Boehringer Ingelheim and FTE payments under that Alliance extended by two years

  • Boehringer Ingelheim filed a Clinical Trials Application for a Nanobody as part of the Alzheimer's collaboration

  • Progress in the Merck Serono collaboration with the selection of a second pre-clinical candidate, ALX-0751 in oncology

  • New partnership signed with Merck & Co for the discovery of Nanobodies targeting a voltage-gated ion channel and an option to a second undisclosed target

  • Entered into a feasibility study with Algeta to explore the use of Nanobodies in radio-immunotherapy for oncology

  • Strengthened the Board of Directors with the appointment of two key industry experts (ex-Amgen and ex-GSK)






Financial highlights



  • Revenue growth of 22% to EUR 26.7M (2011: EUR 21.9M)

  • Cash-in increased by 28% to EUR 36.5M (2011: EUR 28.5M)

  • Operating expenses decreased by 16% to EUR 56.3M (2011: EUR 66.7M)

  • Net loss for the year reduced by 35% to EUR 28.5M (2011: EUR 43.9M)

  • Net cash burn well controlled at just EUR 21.1M

  • Strong year-end financial position of EUR 62.8M in cash, cash equivalents, restricted cash and short-term investments




Post year end highlights



  • Promising 24 week Phase II efficacy and safety results with the anti-IL-6R Nanobody, ALX-0061, in patients with RA

  • Entered into a research collaboration with Spirogen to evaluate the potential of toxin-Nanobody drug conjugates in cancer




Commenting on the 2012 results, Dr Edwin Moses, Chairman and CEO of Ablynx, said:
"2012 was an excellent and rewarding year for Ablynx across all areas of our business. We were able to further demonstrate the power and broad applicability of the Nanobody platform, including the opportunity to deliver Nanobodies directly via the pulmonary route, the potential to design best-in-class molecules and the capability to address difficult disease targets in areas where conventional technologies have not yet been successful. The progression of our existing partnerships and the start of new collaborations are a further endorsement of our achievements to date. During the coming year, we expect important new partnering deals and advances in existing collaborations as some of our partnered programmes move into clinical development. We remain committed to building shareholder value."



Key figures



--------------------------------------------------------------------------
(EUR million)                             2012       2011       % change
--------------------------------------------------------------------------
Revenues                                  26.7       21.9       22%
--------------------------------------------------------------------------
           R&D income                     25.6       19.9       29%
--------------------------------------------------------------------------
           Grants                         1.1        2.0        (45%)
--------------------------------------------------------------------------
Operating expenses                        (56.3)     (66.7)     (16%)
--------------------------------------------------------------------------
           R&D                            (46.9)     (56.3)     (17%)
--------------------------------------------------------------------------
           G&A                            (9.4)      (10.4)     (10%)
--------------------------------------------------------------------------
Other operating income/(expense)          (0.2)      (0.7)      (71%)
--------------------------------------------------------------------------
Operating result                          (29.8)     (45.5)     35%
--------------------------------------------------------------------------
Finance income (net)                      1.3        1.6        (23%)
--------------------------------------------------------------------------
Net result                                (28.5)     (43.9)     35%
--------------------------------------------------------------------------

--------------------------------------------------------------------------
Cash burn                                 (21.1)     (32.0)     (34%)
--------------------------------------------------------------------------
Cash at year end(1)                       62.8       83.8       (25%)
--------------------------------------------------------------------------




(1) including EUR 2.7 million restricted cash



About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com : ctt.marketwire.com/?release=990760&id=2673325&type=1& .. .



complete version of the press release http://hugin.info/137912/R/1681214/549494.pdf : ctt.marketwire.com/?release=990760&id=2673328&type=1& ..




For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com :

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com :
Follow us on Twitter @AblynxABLX

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx@mcomgroup.com : docid: 13990760.nitf -->



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com